Full-Time

Manager – Distribution Center Analytics & Insights

Deadline 9/19/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$102k - $177.1k/yr

+ Long-term incentive program

Jacksonville, FL, USA

In Person

Fully onsite in Jacksonville.

Bachelor's, Master's

Category
Data & Analytics
Required Skills
Power BI
Agile
Python
Supply Chain Management
Six Sigma
Data Visualization
SQL
Data Engineering
Tableau
Data Modeling
Data Governance
Databricks
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A bachelor's degree in Data Analytics, Supply Chain, Operations, Industrial Engineering, Finance, Computer Science, Business, or a related field.
  • A minimum of 7 years of progressive experience in analytics, business intelligence, operations, supply chain, distribution, customer service, or a related discipline, including people or team leadership experience.
  • Demonstrated knowledge of high-volume distribution center operations and the data required to manage service, cost, productivity, inventory, capacity, and quality.
  • Experience supporting new product launches, product or fulfillment costing, cost-to-serve analysis, and customer or channel analytics.
  • Experience leading analytics delivery in a complex, cross-functional environment and presenting recommendations to senior leaders.
  • Hands-on experience with modern analytics and visualization tools, large and complex data sets, data models, pipelines, and integrations.
  • Demonstrated change management experience supporting the introduction and adoption of new systems, digital tools, processes, or operating models.
  • Strong communication, problem-solving, prioritization, stakeholder management, and talent development skills.
Responsibilities
  • Set the analytics strategy and delivery roadmap for the Jacksonville Vision Care site and North America Surgical Vision business, while supporting selected global analytics priorities as needed.
  • Lead the design and governance of dashboards, scorecards, data products, models, and recurring business reviews.
  • Establish common data definitions, ownership, controls, and quality standards across source systems.
  • Translate complex analyses into concise recommendations, scenarios, and executive-ready narratives.
  • Prioritize the analytics portfolio based on customer value, operational risk, financial return, regulatory requirements, and team capacity.
  • Provide actionable insights across inbound, receiving, put-away, replenishment, inventory control, order release, picking, packing, shipping, returns, and exception management.
  • Monitor and analyze throughput, order cycle time, on-time and in-full service, productivity, capacity utilization, inventory accuracy, backlogs, defects, and customer-impacting exceptions.
  • Partner with site leaders to identify constraints, conduct root-cause analysis, test improvement opportunities, and quantify operational and financial value.
  • Develop predictive and scenario-based analytics for labor, capacity, volume, inventory, peak planning, and operational risk.
  • Build self-service capabilities and standard work for daily management and continuous improvement routines.
  • Provide analytics leadership for new product launches, including volume and entitlement modeling, item and master-data readiness, slotting and capacity implications, launch dashboards, early-life monitoring, and post-launch stabilization.
  • Develop and maintain product costing, distribution cost, and cost-to-serve analyses.
  • Partner with Finance and Commercial teams to evaluate profitability, service options, channel strategies, and investment decisions using transparent assumptions and scenario models.
  • Integrate distribution, transportation, inventory, order management, and customer service data to create an end-to-end customer-experience view.
  • Identify differences in demand patterns, service expectations, fulfillment economics, and operational requirements across customer channels.
  • Serve as the analytics lead for the new distribution center and Warehouse Management System transformation.
  • Define future-state data, reporting, key performance indicator, integration, governance, and decision-support requirements.
  • Partner with Operations, Technology, system integrators, Engineering, Finance, and functional teams to translate business needs into requirements, acceptance criteria, data models, reports, and scalable analytics solutions.
  • Support data migration, validation, testing, cutover planning, go-live readiness, command-center visibility, hypercare, and post-implementation stabilization.
  • Assess people, process, data, and technology impacts; develop stakeholder, communication, training, adoption, and reinforcement plans.
  • Create readiness and adoption measures, collect user feedback, identify resistance or capability gaps, and adjust enablement plans based on evidence.
  • Protect customer service and operational performance during implementation by identifying dependencies, reporting gaps, and transition risks and driving mitigation plans.
  • Lead, coach, and develop a high-performing team of analytics professionals, establishing priorities, ownership, service expectations, and development plans.
  • Build capabilities in data engineering, business intelligence, advanced analytics, storytelling, operational problem-solving, and stakeholder engagement.
  • Balance recurring operational support with North America Surgical Vision and global analytics requests.
  • Influence senior leaders and cross-functional partners through facts, clear options, and operational understanding.
  • Promote accountability, experimentation, simplification, inclusion, compliance, and continuous learning.
Desired Qualifications
  • A master's degree in a related field.
  • Experience in healthcare, medical device, pharmaceutical, or another regulated environment.
  • Experience with SAP Extended Warehouse Management or another enterprise Warehouse Management System, including implementation, testing, cutover, and hypercare.
  • Experience supporting a greenfield distribution center, major facility expansion, automation deployment, or large-scale operational transformation.
  • Working knowledge of Power BI, Tableau, Databricks, SQL, Python, cloud data platforms, data catalogs, or equivalent technologies.
  • Certification or practical experience in change management, Lean, Six Sigma, Agile, or project management.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.